landmark randomized clinical trials published in 2007 (US) and 2011 (Italy). 7, 8 Both studies demonstrated the ability of preventative therapy to reduce joint damage compared to factor administered after bleeding. The impact of the US study was evident in a 2010 survey of US haemophilia treatment centres (HTCs) in which 66% of severe HA patients received some form of prophylaxis, a 10% increase from 2008. 9 Previous reports suggest that persons with HA are more likely than those with haemophilia B (HB) to use prophylaxis and have revealed variations in prophylaxis use among US HTCs. 9, 10 Possible explanations for lower prophylaxis use in HB include the greater prevalence of mild and moderate HB patients compared to those with HA and a less severe clinical phenotype. 11, 12 Few studies have focused exclusively on prophylaxis in HB because of the difficulty of obtaining a robust sample; therefore much of our knowledge regarding prophylaxis use is based on the HA population. The question of whether persons with severe HB should be placed on a prophylactic regimen as frequently as those with severe HA remains a subject of debate among haemophilia care providers. [13] [14] [15] [16] [17] [18] Using a large national sample, this study (i) examines the prevalence of prophylaxis use among individuals with moderate and severe HB and (ii) investigates the association of prophylaxis use with clinical and demographic factors similar to those previously reported in the HA population.
| METHODS
The Universal Data Collection (UDC) surveillance project was conducted by the CDC and 135 federally funded HTCs in the US to collect a uniform set of clinical outcomes data on persons who received comprehensive care at these centres. More than 18 000 males, representing 85% of persons with haemophilia receiving care at HTCs, were enrolled from 1998 to 2011. 10, 11 From a study population of 3825 males aged 2-79 years diagnosed with HB, we excluded individuals with mild disease (n=943) and clinical or treatment characteristics having the potential to affect weight status or the ability to treat prophylactically, including a diagnosis of HIV or symptomatic liver disease (n=704); inhibitor titre ≥5 Bethesda units (n=21); and immune tolerance therapy at the time of the visit (n=6). Individuals using intermittent prophylaxis (prophylaxis not expected to continue for an indefinite period of time) were excluded (n=6), as were those with incomplete height and weight data at the time of the most recent UDC visit (n=112).
The study sample includes 2428 persons with moderate or severe HB.
Demographic and clinical data were collected from consenting UDC participants by HTC staff members during UDC visits using standardized data collection instruments. The registration form (completed once at enrollment) recorded month and year of birth, gender, race/ethnicity, factor deficiency, diagnosis and baseline factor activity; the annual visit form (completed at subsequent visits) collected visit date, current height, weight, insurance coverage, home infusion status, person performing the infusion (self, family member or medical care provider) and treatment regimen (episodic or prophylaxis). Data from the most recent UDC visit were used in the analyses. 
| Definition of variables

| Statistical methods
We conducted descriptive and bivariate analyses followed by a series of multiple logistic regression models to assess the independent associations of prophylaxis use with demographic and clinical characteristics.
Percentages of age, race/ethnicity, health insurance status, BMI, severity, self-infusion status and geographic location were calculated to describe demographic and clinical characteristics.
The prevalence of prophylaxis use for each level of these variables was calculated. Bivariate analyses with Pearson's chi-square tests were used to assess differences in prophylaxis use within subgroups.
Multiple logistic regression models were developed to examine whether race/ethnicity was associated with the likelihood of using prophylaxis, adjusting for all other variables. Analyses were conducted on the entire sample and then separately on adults (20 years and older) and non-adults (2-19 years) to show differences in prophylaxis use between age groups. Since firstdegree interactions of age with BMI (P=.09) and with race/ethnicity (P=.18) were not significant, we reported the adjusted odds ratios, 95% confidence interval and P values from the main effect models. 19 We then developed additional polynomial logistic regression models using age as a continuous variable to demonstrate the impact of advancing age on the probability of using prophylaxis among the four race/ethnicity subgroups. Figures based on these models illustrate the mean predicted probability of using prophylaxis with advancing age among the study population.
All statistical analyses were based on two-sided tests with a significance level of 0.05 and conducted using SAS 9.3 (SAS Institute, Cary, NC, USA). Percentages in the total column sum to 99%; the remaining 1% is distributed nearly evenly among the four regional categories.
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| Characteristics of the study population
Our sample included 2428 individuals with moderate or severe HB, aged 2-79 years (Table 1) . Half (51%) were aged 2-19, the majority of the study population were (75%) non-Hispanic White and most individuals (90%) had either commercial or publicly funded health insurance. Nearly half (49%) had above-normal BMI; 23% were obese.
Moderate was the most common haemophilic severity (56%). Nearly one-quarter (23%) of all teens aged 12-19 practiced self-infusion, as did more than half of adults (53%) (data not shown).
| Prevalence of prophylaxis use
Proportionate use of prophylaxis was greatest among 6-11-year olds (40%), followed by 2-5-year olds (35%) and teens 12-19 years (32%).
Overall, prophylaxis was used by roughly one-third (35%) of those aged 2-19 years (Table 1 ). Individuals <20 years of age accounted for 73% of prophylaxis users. Among teens on a prophylactic regimen, 33% self-infused (data not shown).
Prophylaxis was used by less than one-fifth (14%) of all adults, and the proportion generally declined steadily with age, although Not surprisingly, prophylaxis was used more by persons with severe than moderate HB and by those with commercial or public insurance vs some other or no health insurance (Table 1) . Prophylaxis use was most common among Hispanic males and least common among non-Hispanic Whites (Figure 1 ). Among adults, the ability to self-infuse appeared to increase prophylaxis use, while overweight and obesity appeared to decrease use. Geographic differences in prophylaxis use fell short of the significant level (P=.053), although the trend suggested highest use in the West and lowest use in the Midwest.
| Association of prophylaxis use with demographic and clinical characteristics
In a multivariate analysis that included all of the studied characteristics (Table 2) 
| DISCUSSION
Prophylaxis is associated with improved health and psychosocial outcomes but is costly. Factor concentrate accounts for most medical expenditures; a recent analysis found the median annual cost of factor for those with severe HA using prophylaxis to be $289 172, compared to $170 037 for episodic treatment. 20 An understanding of utilization patterns is needed to effectively balance health care outcomes and resource utilization, especially as new therapies, such as extended half-life factor products, are introduced.
Among our sample, 24.6% of those with HB used prophylaxis, compared with 47.2% of those in the UDC with HA using prophylaxis. 11 This difference is consistent with Canadian data in which 32%
of those with severe HB used prophylaxis, compared to 69% of those with HA. 14 Evidence that HB may be clinically less severe than HA, possibly due to a milder bleeding phenotype, includes less frequent bleeding in those with HB, lower rates of arthroplasty and lower factor usage. 12, 13, 15 The lower use of prophylaxis use among HB populations T A B L E 2 Independent association of patient characteristics with prophylaxis use by age in males with moderate to severe haemophilia B (HB) may be the result of less severe disease (due to more missense mutations), providers' use of established haemophilia treatment practices and customs, or a combination of these factors. 21 
| Health care coverage
Health care coverage appears essential for accessing prophylactic treatment, as reported by Baker et al. 22 The overall proportion of individuals with HB covered by some form of health care insurance was high (90%), but nearly twice as many adults (13%) Virtually all 2-19-year olds on prophylaxis were covered by some form of insurance (55% commercial insurance and 44% public insurance); only 1% had no coverage. Among adults using prophylaxis, 52%
had commercial insurance, 43% had public insurance and 3% were uninsured. The fact that similar proportions of persons with publicly funded insurance (29%) and commercial insurance (26%) used prophylaxis suggests that insurance type is not a barrier to optimal care
for persons treated at HTCs. Additional studies using socio-economic data would broaden our understanding of barriers to recommended haemophilia treatment among adults.
| Race and ethnicity
Our finding of significantly higher levels of prophylaxis use among
Hispanic individuals compared to other racial/ethnic groups, provided they had insurance [AOR=1.9 (1.4, 2.7), P=.0002, Table 2 Hispanics are unable to access insurance coverage (and therefore prophylaxis) due to lack of legal US residency.
| Increased BMI
Although obesity was significantly associated with lower prophylaxis use only among adults, young persons were disproportionally affected by obesity (19% of 2-11-year olds and 16% of teens, compared to 11% of adults). Among 2-11-year olds, obesity was more prevalent than overweight; among those with obesity, 14% had morbid obesity.
National Health and Nutrition Examination Survey data collected in
2009-2010 indicate that although the prevalence of obesity among the general U.S. population has stabilized among most age groups, it continues to rise among male adolescents. 23 An obesity prevalence approaching 20% among those most likely to use prophylaxis (2-11-year olds) has significant economic implications. Prophylactic regimens can use up to three times more factor concentrate than episodic treatment. 24, 25 Dosing is based on actual, not ideal, body weight; consequently, a prophylactic regimen for an obese or overweight child is more costly than for one of normal weight. Using patient data from one HTC, prophylactic factor costs for 19 overweight or obese 2-19-year olds with severe HA or HB not using a bypassing agent would cost over $1 million per year (ie roughly $50 000 per person on average) more than if they had a normal body weight, not taking into account 340B program subsidies. 26 In our sample, 163 overweight or obese 2-19-year olds were treated prophylactically, using an estimated $8 million dollars more in factor costs than if they were of normal weight. Public funds covered 29% of individuals using prophylaxis. In an era of constrained healthcare resources, monitoring the BMI of young males at risk for obesity and initiating preventive measures must become a priority for HTCs.
| Study limitations
Some limitations should be noted when interpreting our results. Data were collected prior to the introduction of extended half-life factor IX products; widespread adoption of these may alter future patterns of prophylaxis use by making prophylactic treatment more accessible for patients. Our sample was derived from volunteer participants receiving care through federally funded HTCs. The prevalence of HB in our study population (25%) is slightly higher than some published estimates, possibly due to the greater number of blood-borne virus-related deaths among persons with severe HA during the past 25 years. . 27 We also note that the prevalence of individuals with severe HB (45%) is higher than that reported by a Canadian survey of HTCs (32%). 14 Data collected for the UDC surveillance project were not confirmed with pharmacy or home care records. BMI does not distinguish between fat mass and fat-free mass; however, studies demonstrate that the association between BMI and body fat is strong among those with higher BMI levels. 28 Small sample size may be an issue in analyses of subgroups stratified simultaneously by numerous variables, such as Hispanic persons >40 years using prophylaxis.
| CONCLUSION
We found that (i) the overall prevalence of prophylaxis use among males with moderate and severe HB was 25% among individuals with moderate disease and 45% among those with severe disease; and (ii) age and severity are strongly associated with HB prophylaxis use. Prophylactic treatment was associated with young age: 6-11-year olds were the most likely to use prophylaxis, while adults 40 years and older were the least likely to do so. Prophylaxis was used by nearly six times as many individuals with severe disease as those with moderate haemophilia. 
